These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1398306)

  • 21. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
    Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
    Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combined GM-CSF and erythropoietin therapy in myelodysplastic syndrome].
    Egli F; Hofer S; Greminger P; Rhyner K
    Schweiz Med Wochenschr; 1989 Dec; 119(49):1777-80. PubMed ID: 2694367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin.
    Klaesson S; Ringdén O; Ljungman P; Lönnqvist B; Wennberg L
    Bone Marrow Transplant; 1994 Apr; 13(4):397-402. PubMed ID: 8019463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythroid precursor cells in primary acquired and secondary sideroblastic anemia.
    Takaku F; Mizoguchi H; Suda T; Kubota K; Miura Y
    Exp Hematol; 1980; 8 Suppl 8():225-34. PubMed ID: 6962069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes.
    Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM
    Haematologica; 2002 Aug; 87(8):884-6. PubMed ID: 12161367
    [No Abstract]   [Full Text] [Related]  

  • 27. [Current developments in the therapy of the myelodysplastic syndrome].
    de Witte T; Hermans J; van Biezen A; Runde V; Gratwohl A
    Ned Tijdschr Geneeskd; 1995 Oct; 139(42):2135-9. PubMed ID: 7477578
    [No Abstract]   [Full Text] [Related]  

  • 28. Anemia of chronic inflammatory arthritides: treatment with recombinant human erythropoietin.
    Birgegård G; Gudbjrönsson B; Hällgren R; Wide L
    Contrib Nephrol; 1991; 88():295-303; discussion 304-5. PubMed ID: 2040192
    [No Abstract]   [Full Text] [Related]  

  • 29. [Improvement of the anemia associated with multiple myeloma and renal dysfunction by recombinant human erythropoietin].
    Nakata H; Matsuzaki M; Shimamoto Y; Yamaguchi M
    Rinsho Ketsueki; 1990 Oct; 31(10):1752-3. PubMed ID: 2255069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute treatment with recombinant erythropoietin in patients with pre- and postoperative anemia: a clinical report.
    von Bormann B; Weiler J; Aulich S
    Clin Investig; 1994; 72(6 Suppl):S31-5. PubMed ID: 7950170
    [No Abstract]   [Full Text] [Related]  

  • 31. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis.
    Takashina N; Kondo H; Kashiwazaki S
    J Rheumatol; 1990 Jul; 17(7):885-7. PubMed ID: 2213753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin.
    Verbeelen D; Hauglustaine D; Sennesael J
    Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012
    [No Abstract]   [Full Text] [Related]  

  • 33. Recombinant alpha-2a interferon in the treatment of refractory anemia with excess of blasts.
    Rossi G; Pagetto A; Boverio R; Montanaro G
    Haematologica; 1990; 75(1):97-8. PubMed ID: 2338298
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ring sideroblasts].
    Brattås MKL; Reikvam H
    Tidsskr Nor Laegeforen; 2017 Nov; 137(21):. PubMed ID: 29135187
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of differentiation syndrome in an elderly patient with acute promyelocytic leukemia who subsequently developed refractory anemia with ring sideroblasts.
    Denu RA; Henrich Lobo R; Mattison RJ
    Leuk Lymphoma; 2016 Dec; 57(12):2905-2907. PubMed ID: 27073113
    [No Abstract]   [Full Text] [Related]  

  • 36. Erythropoietin: physiologic basis for clinical applications.
    Schuster SJ; Caro J
    Vox Sang; 1993; 65(3):169-79. PubMed ID: 8249358
    [No Abstract]   [Full Text] [Related]  

  • 37. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Komrokji R; Steensma D; Balleari E; Götze KS; Kotsianidis I; Guerci-Bresler A; Stamatoullas A; Sanz GF; Germing U; Fenaux P
    Leuk Res; 2020 Dec; 99():106472. PubMed ID: 33212326
    [No Abstract]   [Full Text] [Related]  

  • 38. Significance of ring sideroblasts in refractory anaemia with excess of blasts.
    Yoshida Y; Oguma S; Uchino H; Maekawa T
    Br J Haematol; 1987 Jan; 65(1):119-20. PubMed ID: 3814521
    [No Abstract]   [Full Text] [Related]  

  • 39. Recombinant growth factors.
    Goodnough LT; Anderson KC
    Transfus Sci; 1995 Mar; 16(1):45-62. PubMed ID: 10155704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of hemolytic anemia due to red blood cell fragmentation using recombinant human erythropoietin.
    Gitler B
    JAMA; 1995 Jul; 274(4):300-1. PubMed ID: 7609253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.